Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology DOI Creative Commons
Yingying Duan, Zhaoshuo Liu, Qilin Wang

et al.

Genes & Diseases, Journal Year: 2024, Volume and Issue: 12(4), P. 101435 - 101435

Published: Sept. 17, 2024

MYC is dysregulated in approximately 70% of human cancers, strongly suggesting its essential function cancer. regulates many biological processes, such as cell cycle, metabolism, cellular senescence, apoptosis, angiogenesis, and immune escape. plays a central role carcinogenesis key regulator tumor development drug resistance. Therefore, one the most alluring therapeutic targets for developing cancer drugs. Although search direct inhibitors challenging, cannot simply be assumed to undruggable. Targeting MYC-MAX complex has been an effective method directly targeting MYC. Alternatively, indirect represents more pragmatic approach, mainly including inhibition transcriptional or translational processes MYC, destabilization protein, blocking genes that are synthetically lethal with overexpression. In this review, we delineate multifaceted roles progression, highlighting spectrum strategies therapy target either indirectly.

Language: Английский

Exploring the anti-hepatocellular carcinoma effects of Xianglian Pill: integrating network pharmacology and RNA sequencing via in silico and in vitro studies DOI
Jihan Huang, Ruipeng Shi, Feiyu Chen

et al.

Phytomedicine, Journal Year: 2024, Volume and Issue: 133, P. 155905 - 155905

Published: July 27, 2024

Language: Английский

Citations

2

A novel small molecule ZYZ384 targeting SMYD3 for hepatocellular carcinoma via reducing H3K4 trimethylation of the Rac1 promoter DOI Creative Commons
Qian Ding, Jianghong Cai, Jin Li

et al.

MedComm, Journal Year: 2024, Volume and Issue: 5(10)

Published: Sept. 15, 2024

SMYD3 (SET and MYND domain-containing 3) is a histone lysine methyltransferase highly expressed in different types of cancer(s) promising epigenetic target for developing novel antitumor therapeutics. No selective inhibitors this protein have been developed cancer treatment. Therefore, the current study describes characterizing small molecule ZYZ384 screened synthesized based on structure. Virtual screening was initially used to identify lead compound followed up by modification get molecules. Several technologies were facilitate about these molecules' binding affinities inhibition activities with protein; activity has assessed vitro using various cell lines. In addition, tumor-bearing nude mice model established, selected determined vivo. Both RNA-seq chip-seq performed explore mechanism. This work identified targeting impaired hepatocellular carcinoma tumor growth reducing H3K4 trimethylation Rac1 promoter triggering cycle arrest through AKT pathway.

Language: Английский

Citations

2

Recent Advances in Bioactivity-Guided Drug Screening Strategies for Pre-Clinical and Clinical Drug Discovery DOI
Simin Chen,

Chenxiao Shen,

Wanyu Li

et al.

TrAC Trends in Analytical Chemistry, Journal Year: 2024, Volume and Issue: 181, P. 118042 - 118042

Published: Nov. 5, 2024

Language: Английский

Citations

2

Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer DOI
Gerhard Hamilton, Sandra Stickler,

Barbara H. Rath

et al.

Current Cancer Drug Targets, Journal Year: 2024, Volume and Issue: 24(9), P. 930 - 940

Published: Jan. 25, 2024

Small cell lung cancer (SCLC) has a dismal prognosis. In addition to the inactivation of tumor suppressors TP53 and RB1, tumor-promoting MYC paralogs are frequently overexpressed in this neuroendocrine carcinoma. SCLC exhibits high resistance second-line chemotherapy all attempts novel drugs targeted therapy have failed so far achieve superior survival. key roles oncogenic process, orchestrating proliferation, apoptosis, differentiation, metabolism. SCLC, MYC-L regulate dedifferentiation cells from Type A (ASCL1 expression) other subtypes. Targeting suppress growth is difficult due lack suitable binding pockets most advanced miniprotein inhibitor Omomyc limited efficacy. may be indirectly

Language: Английский

Citations

1

Exploring the immunometabolic potential of Danggui Buxue Decoction for the treatment of IBD-related colorectal cancer DOI Creative Commons
Yang Zhang, Qianming Kang,

Luying He

et al.

Chinese Medicine, Journal Year: 2024, Volume and Issue: 19(1)

Published: Aug. 29, 2024

Danggui Buxue (DGBX) decoction is a classical prescription composed of Astragali Radix (AR) and Angelicae Sinensis (ASR), used to enrich blood, nourish Qi in Chinese medicine, with the potential recover energy stimulate metabolism. Chronic inflammation risk factor development inflammatory bowel disease (IBD)-related colorectal cancer (CRC). More importantly, AR ASR have anti-inflammatory anti-cancer activities, as well prefiguring effect on inflammation-cancer transformation. We, therefore, aimed review immunometabolism DGBX its components this malignant transformation, provide helpful complement manage IBD-CRC. The present study investigates multifaceted roles entire ASR, including anti-inflammation effects, properties, immune regulation, metabolic regulation. This assessment informed by synthesis scholarly literature, more than two hundred articles retrieved from PubMed, Web Science, Scopus databases within past decades. search strategy employed utilized keywords such "Danggui Buxue", "Astragali Radix", "Angelicae "Inflammation", "Metabolism", alongside related synonyms, particular emphasis high-quality research studies yielding significant findings. modulating holds promise for treatment IBD-related CRC. It particularly relevant given heterogeneity CRC growing trend towards personalized but precise detailed mechanism necessitate further vivo validation extensive clinical substantiate immunometabolic modulation delineate pathways involved.

Language: Английский

Citations

1

A comprehensive review of the classical prescription Yiguan Jian: Phytochemistry, quality control, clinical applications, pharmacology, and safety profile DOI

Changcheng Lu,

Siyuan Zhang,

Si San Lei

et al.

Journal of Ethnopharmacology, Journal Year: 2023, Volume and Issue: 319, P. 117230 - 117230

Published: Sept. 29, 2023

Language: Английский

Citations

2

Common Alterations in Parallel Metabolomic Profiling of Serum and Spinal Cord and Mechanistic Studies on Neuropathic Pain following PPARα Administration DOI
Yuying Zhao, Zijun Wu,

Shu-jing Hao

et al.

Neuropharmacology, Journal Year: 2024, Volume and Issue: 254, P. 109988 - 109988

Published: May 12, 2024

Language: Английский

Citations

0

Anti‐inflammatory effects of natural products from vitamin C‐rich fruits DOI Creative Commons

Sioi Chan,

Ping Xiong,

Min Zhao

et al.

Food Frontiers, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 4, 2024

Abstract Inflammation is a crucial target for therapeutic interventions in many life‐threatening diseases, which sustains ongoing interest the field of inflammation biology. Plant‐derived natural products, rich phytochemicals, have been used as healing agents several diseases since antiquity. These compounds exhibit antioxidant, anti‐inflammatory, and immunomodulatory properties, well gut microbiota modulation. They hold substantial potential promising candidates development novel strategies management inflammation‐associated diseases. This study presents comprehensive overview benefits given from administrating products (e.g., phenols, terpenes, flavonoids, saccharides), with particular emphasis on vitamin C‐rich fruits based high content bioactive anti‐inflammatory properties. Apart acts significant role modulating activation inflammatory reaction. Deviations its composition associated various Furthermore, advancements machine learning contribute to enhancing clinical outcomes disease treatment. Therefore, this work provided some valuable insights elaborating fruits, probiotics agents, utilization computer‐aided drug design techniques.

Language: Английский

Citations

0

Role of Harmaline in Inhibiting c-Myc, Altering Molecular Typing, and Promoting Apoptosis in Triple-Negative Breast Cancer DOI Creative Commons
Haoyi Xu,

Yan Ma,

Huiling Li

et al.

Breast Cancer Targets and Therapy, Journal Year: 2024, Volume and Issue: Volume 16, P. 855 - 866

Published: Dec. 1, 2024

Objective: Triple-negative breast cancer (TNBC) lacks effective targeted, endocrine therapeutic agents and the development of novel is costly time-consuming. The objective this study was to identify pharmaceuticals natural products utilized in clinical practice that have potential inhibit expression Cellular-myelocytomatosis oncogene (c-Myc), based on a review current literature. aim assess effect specified drugs c-Myc TNBC cells, determine most potent inhibitor, evaluate its impact cell proliferation, invasive migration, apoptosis, as well estrogen receptor (ER), progesterone (PR), human epidermal growth factor 2 (HER-2) at both gene protein levels. Explore for treatment or adjuvant therapy triple-negative cancer. Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) Western blot were used quantify Flow cytometry employed measure proliferation while Transwell assay invasion migration. Results: Harmaline emerged strongest significantly decreasing levels cells. It also inhibited invasion, migration promoting apoptosis Additionally, there varying increase ER PR genes proteins. While HER-2 elevated, no significant change Notably, phosphorylated increased. Conclusion: found promote cells by targeting inhibition c-Myc. induced re-expression ER, PR, genes, Keywords: c-Myc, harmaline, molecular typing,

Language: Английский

Citations

0

Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology DOI Creative Commons
Yingying Duan, Zhaoshuo Liu, Qilin Wang

et al.

Genes & Diseases, Journal Year: 2024, Volume and Issue: 12(4), P. 101435 - 101435

Published: Sept. 17, 2024

MYC is dysregulated in approximately 70% of human cancers, strongly suggesting its essential function cancer. regulates many biological processes, such as cell cycle, metabolism, cellular senescence, apoptosis, angiogenesis, and immune escape. plays a central role carcinogenesis key regulator tumor development drug resistance. Therefore, one the most alluring therapeutic targets for developing cancer drugs. Although search direct inhibitors challenging, cannot simply be assumed to undruggable. Targeting MYC-MAX complex has been an effective method directly targeting MYC. Alternatively, indirect represents more pragmatic approach, mainly including inhibition transcriptional or translational processes MYC, destabilization protein, blocking genes that are synthetically lethal with overexpression. In this review, we delineate multifaceted roles progression, highlighting spectrum strategies therapy target either indirectly.

Language: Английский

Citations

0